factually
Index/Topics/SGLT2 inhibitors for cardiorenal protection

SGLT2 inhibitors for cardiorenal protection

The use of SGLT2 inhibitors for cardiorenal protection in patients with low eGFR thresholds, despite reduced glucose-lowering effects.

Fact-Checks

1 result
Jan 18, 2026

What do guidelines recommend for choosing GLP‑1 RA vs SGLT‑2 inhibitor in patients with type 2 diabetes and eGFR <45 mL/min/1.73 m2?

Guidelines converge on a risk‑based, not purely glycemia‑based, choice: SGLT2 inhibitors are recommended for cardiorenal protection down to low eGFR thresholds (often ≥20 mL/min/1.73 m2) despite reduc...